Daiichi Sankyo H1N1, Avian Flu Combo Drug Moves Into Phase III Trials
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo says it has moved into Phase III trials with the first flu drug, CS-8958 (laninamivir), to treat both H1N1 and the avian virus